中(zhong)國(guo)抗體(ti)制藥有(you)限公(gong)(gong)司(si)(si)(「中(zhong)國(guo)抗體(ti)」或「公(gong)(gong)司(si)(si)」,股份代號:3681.HK)專注于(yu)研究、發展(zhan)、制造及商業化免(mian)疫性(xing)疾病療法,主要研制以單(dan)克隆(long)抗體(ti)為基礎的(de)(de)生物(wu)藥。公(gong)(gong)司(si)(si)注重(zhong)科技研發,其旗(qi)艦(jian)產(chan)品SM03為全(quan)球首(shou)項(xiang)用以治(zhi)療類風濕(shi)關節(jie)炎(yan)的(de)(de)潛(qian)在(zai)抗CD22單(dan)抗,已在(zai)中(zhong)國(guo)進(jin)入類風濕(shi)關節(jie)炎(yan)三(san)期臨(lin)床(chuang)試驗,并被列入國(guo)家十三(san)五重(zhong)大新藥創(chuang)制專項(xiang)重(zhong)大項(xiang)目(mu)。此(ci)外還有(you)多個同類靶(ba)點首(shou)創(chuang)(First-in-target)及同類首(shou)創(chuang)(First-in-class)潛(qian)在(zai)在(zai)研藥物(wu),部分(fen)已處于(yu)臨(lin)床(chuang)階段(duan),適應癥覆蓋(gai)類風濕(shi)性(xing)關節(jie)炎(yan)、系統性(xing)紅斑狼瘡、非霍(huo)奇(qi)金(jin)氏淋巴(ba)瘤、哮喘(chuan)等具有(you)重(zhong)大未(wei)滿足臨(lin)床(chuang)需求的(de)(de)疾病。